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Abstract
Background: The use of hospital discharge administrative data (HDAD) has been recommended for automating,
improving, even substituting, population-based cancer registries. The frequency of false positive and false negative
cases recommends local validation.
Methods: The aim of this study was to detect newly diagnosed, false positive and false negative cases of cancer
from hospital discharge claims, using four Spanish population-based cancer registries as the gold standard. Prostate
cancer was used as a case study.
Results: A total of 2286 incident cases of prostate cancer registered in 2000 were used for validation. In the most
sensitive algorithm (that using five diagnostic codes), estimates for Sensitivity ranged from 14.5% (CI95% 10.3-19.6)
to 45.7% (CI95% 41.4-50.1). In the most predictive algorithm (that using five diagnostic and five surgical codes)
Positive Predictive Value estimates ranged from 55.9% (CI95% 42.4-68.8) to 74.3% (CI95% 67.0-80.6). The most
frequent reason for false positive cases was the number of prevalent cases inadequately considered as newly
diagnosed cancers, ranging from 61.1% to 82.3% of false positive cases. The most frequent reason for false
negative cases was related to the number of cases not attended in hospital settings. In this case, figures ranged
from 34.4% to 69.7% of false negative cases, in the most predictive algorithm.
Conclusions: HDAD might be a helpful tool for cancer registries to reach their goals. The findings suggest that, for
automating cancer registries, algorithms combining diagnoses and procedures are the best option. However, for
cancer surveillance purposes, in those cancers like prostate cancer in which care is not only hospital-based,
combining inpatient and outpatient information will be required.
Background
Population-based cancer registries (hereinafter registries)
are usually considered the main tool for cancer surveil-
lance purposes. Unfortunately, there are some geo-
graphic areas which are not covered by a registry [1]
and concerns about rates of underreporting remain cur-
rent [2].
Although some improvements have been made in the
way a registry deals with data, most of the activity is
still managed manually. Additionally, registries gather
information from different sources with a large variation
in their reliability and validity. Finally, all these pro-
cesses imply delays in the production of relevant infor-
mation. Thus, automating all these processes has
become a priority in order to improve cancer registries
accuracy, efficiency and timeliness [3,4].* Correspondence: ebernal.iacs@aragon.es
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The use of secondary databases, particularly those
which provide information on hospital discharges (i.e.
hospital discharges administrative data [HDAD]), has
been recommended for improving registries performance
in terms of the number of incident cancer cases retrieved
[2,5-7]; in some circumstances, they have even been used
as a substitute for a registry [8,9]. However, the nature of
the information (hospital-based data), the purposes for
which it is recorded (not to act as a diseases registry) and
the methodology (based on the information declared by
the clinicians) require local validation.
In fact, some studies have shown variability in the
capacity of HDAD to identify incident cancer cases. For
example, depending on the definition used to name inci-
dent cases, the timeframe of retrieval, or whether the
patient received surgical treatment, positive predictive
values (PPV) ranged from 43% to 92% in breast cancer
[10-12]. Other research, focusing on prostate, lung, col-
orectal, breast, pancreas and endometrial cancer in
elderly Americans showed similar variation in estimates:
sensitivity ranged from 46% in prostate cancer to 82% in
colorectal cancer [13].
As a consequence of these results, positive and nega-
tive false causes have been described. So, prevalent
cases, coding error misclassification (benign, in situ,
etc.), multiple readmissions, coding cancer in a second-
ary diagnostic position or not having a concurrent surgi-
cal procedure in the same episode, have been suggested
causes of false positive cases of incident cancer. Private
hospitalizations, outpatient care, elderly people, patients
with comorbidity or patients admitted for conservative
procedures have been proposed -among others- as
causes of negative false cases of incident cancer [14,15].
Unfortunately, few studies have focused on HDAD
validity in the Spanish context. Recently, a study discussed
this matter comparing colorectal cancer admissions with
cases registered in a Spanish registry [16]. When only the
first diagnostic code was considered, the sensitivity of the
HDAD reached 80% with a positive predictive value of
75%. When all the coded diagnoses were considered, sen-
sitivity rose to 85% reducing the PPV to 64%.
Finally, HDAD validity is expected to be different in
those cases in which variability in medical practice is
relevant. For example, colorectal cancer in which admis-
sion for surgery is the rule and prostate cancer, where
options for treatment go from a watchful waiting strat-
egy (ambulatory care) to a radical prostatectomy (hospi-
tal care) [17]. In fact, for prostatectomy on prostate
cancer, a 7-fold variation was found between high and
low intensity healthcare areas in Spain [18].
The aim of our study was to detect incident, false
positive and false negative cases of cancer on hospital
discharge claims, using four Spanish population-based
cancer registries as the gold standard. Prostate cancer
was used as a case study.
Methods
Design
We firstly carried out a linking-records-based validation
study. Using a cross-section of 1998 to 2000 HDAD
from 48 hospitals in 4 Spanish regions (Basque Country,
Region of Murcia, and the provinces of Granada and
Zaragoza), prostate cancer discharges in 2000 were stu-
died. Public hospitals provided the information for the
study, except in the case of Murcia where information
from private hospitals was also included.
For validation purposes, the lack of an independent
gold standard obliged us to use cancer registries,
although some overlapping might be found because
HDAD is usually a basic source of information for can-
cer registries. The four Spanish population-based regis-
tries, used as the gold standard in the study, cover a
population of about 2.5 million inhabitants, and fulfil
international standard procedures [19]. The Health
Regional Authorities in Andalusia, Aragon, Basque
Country and Region of Murcia, which are in charge of
both the cancer registries and the HDAD, allowed its
use for the purposes of this study.
Linking-record process
Once prostate cancer cases were retrieved from HDAD, a
linking-record process was developed in order to match
these cases with those identified as incident cases in 2000
by each local registry. The process basically consisted in
matching -both in a deterministic or a probabilistic way-
each prostate cancer case by hospital record ID, hospital
of admission, date of birth, insurance identification num-
ber or name of patient [20]. All cases were checked after
automatic linking process finished. (Figure 1)
As a consequence, four matched datasets were
obtained from this process and used in the analyses: the
Basque Country Dataset (BD), the Granada Dataset
(GD), the Murcia Dataset (MD) and the Zaragoza Data-
set (ZD).
Main endpoints
HDAD validity for detecting incident cases of prostate
cancer was assessed by estimating sensitivity, positive
predictive value and analysing false negative and false
positive underlying causes for the most sensitive (i.e.,
more helpful for cancer surveillance purposes) and the
most predictive strategy of analysis (i.e., more useful for
automating data).
Definition of malignant prostate cancer incident case
The definition of a malignant prostate cancer was based
on combinations of diagnostic and procedure codes
Bernal-Delgado E et al. BMC Health Services Research 2010, 10:9
http://www.biomedcentral.com/1472-6963/10/9
Page 2 of 8
according to the International Classification of Diseases,
9th Revision, Clinical Modification ICD-9-CM (table 1)
Among those selected “cases under study”, both inci-
dent and prevalent cases were found. To reduce the
possibility of retrieving prevalent cases (as opposed to
incident ones), an active search was made in the two
previous years (1998 and 1999). Those episodes with the
same diagnostic code, metastases codes, and those with
a code of cancer antecedent or episode of care for can-
cer were excluded.
As previous work suggests [11,13], in order to get a
more specific definition, four different strategies (com-
puting algorithms) combining both the number of codes
and the information from diagnoses and procedures
were checked. These four strategies were: 1) selecting
episodes which had an eligible code in the main diag-
nostic position (Algorithm 1); 2) selecting episodes
which had an eligible code in the first five diagnostic
positions (Algorithm 2); 3) selecting episodes that had a
code of cancer in the main diagnostic position and also
a related surgical procedure (Algorithm 3); and 4)
selecting episodes which had a code of cancer among
the first five diagnostic positions and a related surgical
procedure (Algorithm 4). When procedures were used
(i.e. algorithm 3 and 4), five first positions were
considered.
Therefore, once cancer codes were selected, possible
prevalent cases were excluded by searching in the two
previous years. Then, the four aforementioned strategies
were checked to select the best in detecting “incident
cancer cases”.
Analysis
Number and percentage of matched cases and causes of
failure were analyzed. Among matched and unmatched
Figure 1 Flowchart representing the linking record process.
Table 1 Codes defining malignant prostate neoplasm
ICD 9th-CM codes
Inclusion Codes Diagnostic codes
185
Surgical codes
605 6069, 623 - 6242, 6029, 603, 604, 6061, 6062
Exclusion Codes Antecedent of cancer at the same site
V1046
Antecedent of episode of care for prostate cancer
V581, V580, V660, V661, V662, V670, V671, V672
Miscellaneous
V711
Bernal-Delgado E et al. BMC Health Services Research 2010, 10:9
http://www.biomedcentral.com/1472-6963/10/9
Page 3 of 8
cases, underlying causes of disagreement were studied;
thus, false positive and false negative cases were
recorded and discussed.
Finally, in order to determine the validity of the
HDAD to detect incident cases of cancer, two indexes
were estimated: 1) Sensitivity, as the percentage of
cases considered incident cases in the HDAD within
those true incident cases recorded in the registry; and,
2) the Positive Predictive Value as the percentage of
true cases within those cases considered incident cases
in the HDAD. Both indexes were calculated for each
one of the four different strategies and 95% confidence
intervals (CI95%) were estimated using an exact bino-
mial test [21]. All analyses were conducted using
STATA v9.
Results
A total of 2286 cases of prostate cancer registered in
2000 were used. 231 cases were included from Granada
cancer registry (crude rate of 57.8 per 105 inhabitants);
1150 cases from Basque Country cancer registry (crude
rate of 113.4 per 105 inhabitants); 411 cases from Mur-
cia cancer registry (crude rate of 71.4 per 105 inhabi-
tants) and 494 cases from Zaragoza cancer registry
(crude rate of 117.9 per 105 inhabitants). Table 2 com-
pares these facts with the number of cases retrieved
from the HDAD once algorithms were implemented.
Validity of HDAD to detect incident cases of prostate
cancer
The most sensitive strategy (algorithm 2) was that which
used diagnostic codes from position 1 to 5; whereas the
most predictive (algorithm 4) (i.e. the highest PPV) was
that which considered concurrent diagnoses and proce-
dures from positions 1 to 5 (Table 2).
However, estimates for both Sensitivity and PPV were
moderate to low. With regard to sensitivity, as expected,
strategies based on diagnoses performed a little better
than strategies based on concurrent diagnoses and pro-
cedures. However, except in ZD, first and second algo-
rithm estimates scored under 25%. Although PPV
performed better than sensitivity in BD and ZD (62%
[CI95%: 55.6 to 68.0] in the former and 74.3% [CI95%:
67.0 to 80.6] in the latter), GD and MD included the
50% value (table 2).
False negative and false positive underlying causes
With regard to the most sensitive algorithm
(Table 3), it should be noted that all datasets shared an
important source of false negative cases, that is, those
prostate cancer patients without admission (i.e. cases
that were only treated as outpatients). In fact data ran-
ged from 79% of cases in GD and MD to 39.3% in BD,
with a 72.7% in ZD.
However, the main source of false negative cases in
BD was private hospitalization (i.e. the lack of informa-
tion from a set of hospitals without HDAD) during the
period of study. This cause was responsible of 42.7% of
BD false negatives. On the other hand, cases admitted in
2000 but discharged in 2001 were a relevant source of
false negative cases in BD (11.3%), MD (12.9%) and ZD
(16%).
Considering the false positive causes related to the
most sensitive strategy, all datasets shared a very com-
mon cause; cases considered “incident cases” by the
algorithm that actually were “prevalent cases” (data ran-
ged form 61.1% in MD to 82.3% in GD). It should be
noted that the following source of false positive cases
was a coding error or clinical diagnosis misclassification
in discharge records; this represented 4.3% in BD, 10.3%
in GD, 16.4% in ZD and 23.9% in MD.
With regard to the most predictive algorithm
(Table 4), besides the already referred causes, an addi-
tional source of false negative cases was found: cases
lost due to the restrictions of the algorithm itself. Data
ranged from 11.8% of false cases in GD to 26.9% in ZD,
suggesting coding differences among local HDADs.
On the other hand, incident cases which were actually
prevalent were also the main cause of false positive
cases in the most predictive algorithm (data ranged
from 66.7% of false cases in MD to 82.1% in BD).
Discussion
A linking-records-based validation study was carried out
to determine whether the HDAD might be a useful tool
to identify incident cases of prostate cancer. 2286 inci-
dent prostate cancer cases, recorded in four Spanish
population-based cancer registries, were used to esti-
mate its validity. Four algorithms were developed to
detect incident cases. Those using only diagnostic codes
were the most sensitive strategies although sensitivity
scored around 25%; those using concurrent information
about procedures were the most predictive, although
positive predictive value scored close to 50%.
There is no recent literature available for comparison.
Some international literature showed higher values for
sensitivity [13] in prostate cancer, although the context
was extremely different (cases attended 20 years ago, a
completely different prostate cancer management, differ-
ent use of administrative databases and a completely dif-
ferent healthcare system) to allow a reasonable
discussion about the consistency of our results. Unfortu-
nately, in our context, the only published study evalu-
ated colorectal cancer [16].
Nevertheless, the analysis of false positive and false
negative underlying causes has provided very useful
insights. Three possible sources of failure to detect inci-
dent cases could be described in our study: the HDAD
Bernal-Delgado E et al. BMC Health Services Research 2010, 10:9
http://www.biomedcentral.com/1472-6963/10/9
Page 4 of 8
itself, the algorithms to detect cancer, and the features
of this specific cancer site.
Shortcomings for incident case detection using the HDAD
Firstly, although HDAD has been a compulsory informa-
tion system for public institutions since the mid 90s in
Spain, it was not mandatory for private hospitals. Thus,
it must be expected that in those places where popula-
tion is served by hospitals not required to provide hos-
pital information, the capacity of HDAD to find cases
when they exist in the registry will be limited.
In fact, this is the reason for the high number of false
negative cases in the Basque Country, region in which
the private-public mix is more influential in prostate
cancer treatment (32% of prostate cancers registered the
year under study were considered false negatives for this
cause). In the remaining regions where this effect is
expected to be less important, the percentage of false
negative cases was lower: only 27 cases in Granada (12%
of registered cancer), 25 cases in Zaragoza (5%) and 1
case in Murcia (0.3%) where information about private
hospitals was also included.
Secondly, the population covered by a registry and the
population attended by a hospital (from which the cases
were retrieved) are different. Procedures like radical
prostatectomy are usually delivered in high-volume hos-
pitals, in which populations from different healthcare
areas or regions are regularly referred to. These cases
were identified as false positive cases because these
patients belonged to a different area than that covered
by the registry.
Although this was not an important source of false
positive cases, in the most sensitive algorithm, figures
ranged from 1.3% in ZD to 4.5% in BD.
Thirdly, coding processes seem to act as a potential
source of variation within and among regional settings
in different ways. In fact, empirical data show figures
that deserve some comment. False positive diagnoses (i.
e. HDAD registered prostate cancer when other type of
cancer or even a benign tumour was registered in the
registry) varied among regions. Taking into account the
most sensitive definition, over all prostate cancer cases
identified by HDAD, false positive diagnoses ranged
from 4.3% in BD to 23.9% in MD (previous research
found 7% of inappropriate use of codes [11]).
Another element that potentially could affect the
number of false negative cases is the number of ICD
codes registered for each patient, in each hospital, both
in diagnoses and procedures. Slight differences have
been found among registries: HDAD in Granada regis-
tered a mean of 4 diagnoses and 2 procedures; Basque
Country recorded a mean of 3 diagnoses and 1 proce-
dure, Murcia registered a mean of 5 diagnoses and 2.4
procedures and Zaragoza registered a mean of 4.2 diag-
noses and 2.1 procedures. However, although a potential
Table 2 Sensitivity (S) and Positive Predictive Values (PPV). (by Algorithm and Region)
Algorithm 1
Dx1
Algorithm 2
Dx1 to Dx5
Algorithm 3
Dx1&Pr1-Pr5
Algorithm 4
Dx1-Dx5&Pr1-Pr5
Granada
Cases identified in Registry 231 231 231 231
Cases identified in HDAD 55 113 33 33
Sensitivity (CI95%) 12.9 (8.9-18.0) 14.5 (10.3-19.6) 8.7 (5.4-13.1) 8.7(5.4-13.1)
PPV (CI95%) 54.5 (40.6-68.0) 39.8 (30.7-49.5) 60.6 (42.1-77.1) 60.6 (42.1- 77.1)
Basque Country
Cases identified in Registry 1150 1150 1150 1150
Cases identified in HDAD 372 632 245 250
Sensitivity (CI95%) 17.8 (15.6-20.1) 24.3 (21.8-26.8) 13.2 (11.3-15.3) 13.5 (11.5-15.6)
PPV (CI95%) 55.1 (49.9-60.2) 44.1 (40.2-48.1) 62.0 (55.6-68.1) 62.0 (55.6-68.0)
Murcia
Cases identified in Registry 411 411 411 411
Cases identified in HDAD 118 218 56 59
Sensitivity (CI95%) 14.4(11.1-18.1) 23.6 (19.5-28.0) 7.3 (4.9-10.2) 8.0 (5.5-11.0)
PPV (CI95%) 50.0 (40.6-59.3) 44.5 (37.7-51.3) 53.6 (39.7-67.0) 55.9 (42.4-68.8)
Zaragoza
Cases identified in Registry 494 494 494 494
Cases identified in HDAD 217 378 169 171
Sensitivity (CI95%) 30.4 (26.3-34.4) 45.7 (41.4-50.1) 25.3 (21.5-29.3) 25.7 (22.0-29.8)
PPV (CI95%) 69.1 (64.1-74.2) 59.8 (55.4-64.8) 74.0 (66.6-80.4) 74.3 (67.0-80.6)
S: sensitivity, PPV: Positive Predictive Value; CI95%: Confidence Interval assuming a type I error of 5%
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cause, the number of false negative cases for this reason
was negligible.
Shortcomings related with the algorithms
As expected [11,13] algorithms including concurrent
procedures were more “restrictive”, and their positive
predictive values were higher than those without surgi-
cal codes. As a consequence of being so “specific” there
was a significant loss of prostate cancer cases (i.e. false
negative cases): 25 in GD, 125 in BD, 52 in MD and 99
in ZD. These numbers represented 11.8% of cases
detected in GD, 12.6% in BD, 13.7% in MD and 26.9%
in ZD and probably refers to those cases admitted for
diagnostic tests that did not require surgical treatment.
On the other hand, a noticeable number of false nega-
tive cases were due to the fact that there were patients
diagnosed in 2000 (i.e. admission to the hospital was in
2000) but they were discharged in 2001. This ranged
from 1.4% of cases in GD to 11.7% of cases in ZD. How-
ever, flagging properly theses cases, for example by
opening the timeframe two months forward, we would
barely increase sensitivity in a 10%, remaining figures
under 50%.
An additional source of false negative cases could be
found in the exclusion of metastatic disease in the defi-
nition of incident case; it would the case for patients
that initially present with metastases and the original
prostatic tumour is only found once they are discharged.
These patients would be flagged as false negatives if they
are discharged without definitive diagnoses. None out of
the 58 cases which could potentially be affected in our
sample was actually misclassified.
Finally, although several strategies were used to reduce
the number of prevalent cases (patients with an episode
were followed backwards two years and specific exclu-
sion criteria were used) a remarkable number of preva-
lent cases were retrieved by the algorithm. As expected
the most specific strategy (algorithm 4) identified less
prevalent cases than the most sensitive one (algorithm
2); however, 9(69.2%) prevalent cases were found in GD,
78 (82.1%) in BD, 14(66.7%) in MD and 36(81.8%) in
ZD. When we reviewed cases registered in 1997 and
earlier, we found a 48% of prevalent cases. This finding
suggests that considering a timeframe backward of 5
years would be better in terms of gaining higher positive
predictive values.
Shortcomings related with the cancer site
Long survival cancers, like prostate cancer, are supposed
to have more hospital readmissions than aggressive
short survival cancers. Probably, the unexpected number
of prevalent cases is related with us having decided to
use too short a timeframe. In fact, in a ten-year period
study Brackley et al. [22] found a rate of false positive
as small as 1%, although authors recognised a significant
overlapping between HDAD and registries.
But the most important element to be considered is
the different manner in which healthcare services man-
age prostate cancer. In fact, 947 cases (41% of the total
sample of prostate cancer registered by the 4 registries
Table 3 Causes underlying positive and negative false cases in prostate cancer (with regard to the highest sensitive
algorithm)
Granada Dataset
n (%)
Basque Country Dataset
n (%)
Murcia
Dataset
n (%)
Zaragoza
Dataset
n (%)
False negative cases
• Cases from private hospital in 2000 27 (14.5) 372 (42.7) 1 (0.3) 25 (9.3)
• Cases admitted in 2000 but discharged in 2001 3 (1.6) 98 (11.3) 41 (12.9) 43 (16.0)
• Cases coded in dx6 position or more 0 (0) 7 (0.8) 3 (0.9) 0 (0)
• False negative diagnoses 7 (3.8) 46 (5.3) 3 (0.9) 2 (0.7)
• Ambulatory care (instead of in-hospital care) 147 (79.0) 343 (39.3) 252 (79.7) 195(72.7)
• Loss using the algorithm 0 (0) 0 (0) 3(0.9) 0 (0)
• Other causes 2 (1.1) 4 (0.5) 13 (4.1) 3 (1.1)
186(100) 871(100) 316(100) 268(100)
False positive cases
• Cases registered in 2001 0 (0) 8 (2.3) 1 (0.8) 0 (0)
• Prevalent cases 56 (82.3) 280 (79.5) 74 (61.1) 122 (80.3)
• False positive diagnoses 7 (10.3) 15 (4.3) 29 (23.9) 25 (16.4)
• Missing in the registry 0 (0) 23 (6.5) 0 (0) 3 (1.9)
• Other residence than that covered by the registry 3 (4.4) 16 (4.5) 3 (2.5) 2 (1.3)
• Other causes 2 (2.9 10 (2.8) 14 (11.6) 0 (0)
68(100) 352(100) 121(100) 152(100)
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in 2000) were treated in ambulatory settings, being con-
sidered false negative cases by our methodology [147
cases in GD, 343 in BD, 262 in MD and 195 in ZD].
Thus, the more hospital-based the care provided the
more probability of registering positive true cases by
using the HDAD. This hypothesis was tested for breast
cancer in a study that compared the Medicare and
SEER registries agreement: concordance was consider-
ably higher if surgery was performed (85% vs 50% when
only biopsy was provided) [23].
Preliminary data from colorectal cancer and female
breast cancer in Spain, two sites in which surgery is
needed, show a better performance of positive predictive
value: our context is consistent with this hypothesis: col-
orectal cancer and breast cancer showed a higher posi-
tive predictive value (up to 89% and up to 86%,
respectively) [24-26].
Looking at these findings, we would be able to hypothe-
size that a good performance of our algorithms is expected
in those cancers in which surgical treatment is needed and
variations in surgical population rates are small (e.g. lar-
ynx, endometrial, colorectal or breast cancer). Conversely,
those cancers with high uncertainty about the effectiveness
of surgical intervention (e.g. prostate, oesophagus, pan-
creas, lung cancer) will perform poorly.
Conclusions
Following the findings and discussion, in cancers like
prostate cancer, we might distinguish some implications
for cancer registries:
a) For automating the retrieval of incident cases, using
algorithms combining diagnoses and procedures is a
better option; however, opening the timeframe, being
careful with the way cancer is registered, and properly
recording the post-code where the patients live are
important issues to be addressed.
b) On the other hand, some improvements should be
implemented in the algorithms for cancer surveillance
purposes. In this case, to widen the timeframe forward
and to get cases from private institutions are important
issues; however, the critical point is the need to combine
inpatient and outpatient information in those cancers
like prostate cancer, in which care is not only hospital-
based.
HDAD seems to be a useful instrument to help cancer
registries to reach their goals. Nevertheless, differences in
the way cancers are managed across the healthcare system
and the variability within and between registry procedures,
suggest the need to be careful when HDAD is used.
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